HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List

Stock News

12/07

HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.

FULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1129047194"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129047194\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129047194?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129047194","market":"sg","top_or_hot":-1,"title":"HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List","media":"Stock News","content":"<p>HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.</p>\n<p>FULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (02696): FULINNING® (Fulvestrant Citrate Capsules) Included in China's National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 18:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.</p>\n<p>FULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1129047194","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129047194","pubTimestamp":1765104168,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"复宏汉霖(02696)：福林宁®（枸橼酸氟维司群胶囊）纳入中国国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"HENLIUS (02696) announced that FULINNING® (Fulvestrant Citrate Capsules) has been included in the 2025 National Reimbursement Drug List (NRDL) under Category B. The approved indication covers its use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer who have progressed after prior endocrine therapy. The updated NRDL will take effect on January 1, 2026.\nFULINNING® is an innovative CDK4/6 small molecule inhibitor licensed by the company. It was first approved in China in May 2025 for the above-mentioned indication. In September 2025, an additional indication was approved for FULINNING® in China, allowing its use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}